Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ficonalkib - Shouyao Holdings

Next Previous
X
Search
Drug Profile

Ficonalkib - Shouyao Holdings

Alternative Names: CT-3505; LTK tyrosine kinase inhibitor - Shouyao Holdings; SY-3505

Latest Information Update: 15 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shouyao Holdings
  • Class Antineoplastics; Piperidines; Pyrimidines; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 12 Feb 2024 Shouyao holdings plans a phase III trial for Non-small cell lung cancer (First-line therapy, Late-stage disease) in China (PO, capsule) in May 2024 (NCT06254599)
  • 28 Sep 2023 Chemical structure information added
  • 07 Sep 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in China (PO) (NCT06037317)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top